100 related articles for article (PubMed ID: 18817351)
1. [Fatty acid synthase and prostate cancer].
Wang KF; Wu B
Zhonghua Nan Ke Xue; 2008 Aug; 14(8):740-2. PubMed ID: 18817351
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.
Rossi S; Graner E; Febbo P; Weinstein L; Bhattacharya N; Onody T; Bubley G; Balk S; Loda M
Mol Cancer Res; 2003 Aug; 1(10):707-15. PubMed ID: 12939396
[TBL] [Abstract][Full Text] [Related]
3. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase: a metabolic oncogene in prostate cancer?
Baron A; Migita T; Tang D; Loda M
J Cell Biochem; 2004 Jan; 91(1):47-53. PubMed ID: 14689581
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthase and cancer: new application of an old pathway.
Kuhajda FP
Cancer Res; 2006 Jun; 66(12):5977-80. PubMed ID: 16778164
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence.
Myers RB; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
J Urol; 2001 Mar; 165(3):1027-32. PubMed ID: 11176534
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells.
Menendez JA; Lupu R
Arch Immunol Ther Exp (Warsz); 2004; 52(6):414-26. PubMed ID: 15577743
[TBL] [Abstract][Full Text] [Related]
8. Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: an interinstitutional study.
Camassei FD; Jenkner A; Ravà L; Bosman C; Francalanci P; Donfrancesco A; Alò PL; Boldrini R
Med Pediatr Oncol; 2003 May; 40(5):302-8. PubMed ID: 12652618
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex.
Notarnicola M; Altomare DF; Calvani M; Orlando A; Bifulco M; D'Attoma B; Caruso MG
Oncology; 2006; 71(5-6):327-32. PubMed ID: 17687193
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.
Wang YY; Kuhajda FP; Li J; Finch TT; Cheng P; Koh C; Li T; Sokoll LJ; Chan DW
J Exp Ther Oncol; 2004 Jul; 4(2):101-10. PubMed ID: 15500005
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells.
Menendez JA; Lupu R
Curr Opin Clin Nutr Metab Care; 2006 Jul; 9(4):346-57. PubMed ID: 16778562
[TBL] [Abstract][Full Text] [Related]
12. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid synthase activity in tumor cells.
Little JL; Kridel SJ
Subcell Biochem; 2008; 49():169-94. PubMed ID: 18751912
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
[TBL] [Abstract][Full Text] [Related]
15. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy.
Davidson SD; Cherry JP; Choudhury MS; Tazaki H; Mallouh C; Konno S
J Urol; 1999 Feb; 161(2):690-1. PubMed ID: 9915484
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer.
Liu Y
Prostate Cancer Prostatic Dis; 2006; 9(3):230-4. PubMed ID: 16683009
[TBL] [Abstract][Full Text] [Related]
17. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
[TBL] [Abstract][Full Text] [Related]
18. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
19. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.
Na M; Jang J; Min BS; Lee SJ; Lee MS; Kim BY; Oh WK; Ahn JS
Bioorg Med Chem Lett; 2006 Sep; 16(18):4738-42. PubMed ID: 16870425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
